Recursion Pharmaceuticals, Inc. (RXRX)

Recursion Pharmaceuticals Statistics

Total Valuation

RXRX has a market cap or net worth of $1.65 billion. The enterprise value is $1.40 billion.

Market Cap	1.65B
Enterprise Value	1.40B

Important Dates

The last earnings date was Wednesday, November 6, 2024, after market close.

Earnings Date	Nov 6, 2024
Ex-Dividend Date	n/a

Share Statistics

RXRX has 286.84 million shares outstanding. The number of shares has increased by 23.57% in one year.

Current Share Class	279.60M
Shares Outstanding	286.84M
Shares Change (YoY)	+23.57%
Shares Change (QoQ)	+16.68%
Owned by Insiders (%)	6.62%
Owned by Institutions (%)	91.05%
Float	252.23M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	22.76
Forward PS	25.54
PB Ratio	3.29
P/TBV Ratio	3.81
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	21.41
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.35, with a Debt / Equity ratio of 0.17.

Current Ratio	4.35
Quick Ratio	3.95
Debt / Equity	0.17
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-398.03

Financial Efficiency

Return on equity (ROE) is -78.49% and return on invested capital (ROIC) is -44.73%.

Return on Equity (ROE)	-78.49%
Return on Assets (ROA)	-36.40%
Return on Capital (ROIC)	-44.73%
Revenue Per Employee	$130,368
Profits Per Employee	-$755,502
Employee Count	500
Asset Turnover	0.10
Inventory Turnover	n/a

Taxes

Income Tax	-5.20M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -16.18% in the last 52 weeks. The beta is 0.80, so RXRX's price volatility has been lower than the market average.

Beta (5Y)	0.80
52-Week Price Change	-16.18%
50-Day Moving Average	6.63
200-Day Moving Average	8.33
Relative Strength Index (RSI)	37.10
Average Volume (20 Days)	7,308,352

Short Selling Information

The latest short interest is 62.43 million, so 21.76% of the outstanding shares have been sold short.

Short Interest	62.43M
Short Previous Month	59.44M
Short % of Shares Out	21.76%
Short % of Float	24.75%
Short Ratio (days to cover)	14.80

Income Statement

In the last 12 months, RXRX had revenue of $65.18 million and -$377.75 million in losses. Loss per share was -$1.54.

Revenue	65.18M
Gross Profit	-262.71M
Operating Income	-395.25M
Pretax Income	-380.29M
Net Income	-377.75M
EBITDA	-364.15M
EBIT	-395.25M
Loss Per Share	-$1.54

Balance Sheet

The company has $427.65 million in cash and $90.63 million in debt, giving a net cash position of $337.02 million or $1.17 per share.

Cash & Cash Equivalents	427.65M
Total Debt	90.63M
Net Cash	337.02M
Net Cash Per Share	$1.17
Equity (Book Value)	524.56M
Book Value Per Share	1.83
Working Capital	365.28M

Cash Flow

In the last 12 months, operating cash flow was -$317.82 million and capital expenditures -$14.46 million, giving a free cash flow of -$332.29 million.

Operating Cash Flow	-317.82M
Capital Expenditures	-14.46M
Free Cash Flow	-332.29M
FCF Per Share	-$1.16

Margins

Gross Margin	n/a
Operating Margin	-606.35%
Pretax Margin	-587.49%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	-689.36%

Dividends & Yields

RXRX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-23.57%
Shareholder Yield	-23.57%
Earnings Yield	-22.63%
FCF Yield	-19.90%

Analyst Forecast

The average price target for RXRX is $9.25, which is 60.87% higher than the current price. The consensus rating is "Buy".

Price Target	$9.25
Price Target Difference	60.87%
Analyst Consensus	Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

RXRX has an Altman Z-Score of 2.47 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.47
Piotroski F-Score	3